Outpost Bio is decoding the hidden interactions that drive human biology. The company combines high-throughput assays of human-derived microbial communities with machine learning to build frontier models that reveal causal pathways - not just correlations. Headquartered in Boston and London, the company enables any partner developing molecules that go into or onto humans to predict microbe-mediated metabolism, toxicity, and response - making human microbiology computable for the first time.
- Life Sciences
- London, United Kingdom
- £2.6m
- outpost.bio
- Update Information
More venture news
- 19 Jun 2026

Houdini BioHoudini Bio launches with a £1.5m pre-seed led by SCVC to tackle gene silencing with machine learning DNA design platform
Pre-seedLife Sciences - 3 Jun 2026

ApohaApoha unlocks £27m in funding led by Singular to measure how molecules and materials behave under real-world conditions
EquityLife Sciences - 2 Jun 2026

IMU BiosciencesIMU Biosciences unlocks £40m Series A led by IQ Capital and Molten Ventures to decode the immune system with high-resolution blood analysis
Series ALife Sciences
